RxDoctor Payments DataLook up a doctor →

Alfred Barritt, MD

Gastroenterology · Chapel Hill, NCNPI 1154395879

Payments from drug & device makers

$1,349,669in general payments, 2019–2025

Across 522 payments — averaging $2585.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$308K
  • GSK$238K
  • AbbVie$223K
  • Bausch Health US, LLC$197K
  • Madrigal Pharmaceuticals$117K
  • Intercept Pharma Europe Ltd.$64K
  • plus $203K from 18 others

What the payments were for

  • Consulting fees$61,82029%
  • Speaking & faculty fees$111,18453%
  • Travel & lodging$30,46614%
  • Food & beverage$6,9803%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,349,669 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$34,437
Medicare patients
166
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin104$335,184
RezdiffraResmetirom13$59,433
Envarsus XrTacrolimus15$31,978
Sirolimus14$11,683
Ursodiol52$11,314
EliquisApixaban12$6,681
Tacrolimus85$5,435
Azathioprine24$3,172
Mycophenolate Mofetil32$2,017
Mycophenolic AcidMycophenolate Sodium28$1,851
Lactulose36$1,042
Spironolactone23$466
Doxepin Hcl13$300
Furosemide36$230
Omeprazole18$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,355$335,184104 claims
Madrigal PharmaceuticalsRezdiffra$117,475$59,43313 claims
PfizerEliquis$20,738$6,68112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →